Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca To Launch Phase I Trial Of Liver Cancer Drug Developed In China

This article was originally published in PharmAsia News

Executive Summary

An AstraZeneca drug said to be the first of its kind to be developed in China by a multinational drug maker is about to undergo clinical trials to see if it is effective for treating liver cancer. The disease is China's second-largest killer, lung cancer being first. China's State FDA has approved the Phase I clinical trial, a step somewhat unusual since China often relies on results from a first-stage abroad before approving one locally. The drug was developed through global chemistry research by the company's Chinese innovation center, its sole research facility in Asia. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel